PMID- 17288697
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 2
DP  - 2007 Feb
TI  - Effect of inhaled insulin on patient-reported outcomes and treatment preference 
      in patients with type 1 diabetes.
PG  - 435-42
AB  - OBJECTIVE: To compare patient-reported outcomes and treatment preference between 
      preprandial inhaled insulin and preprandial subcutaneous (SC) insulin in the 
      context of a clinical trial of crossover design with a primary objective of 
      comparing HbA(1C) between groups. RESEARCH DESIGN AND METHODS: Multi-center, 
      randomized, open-label, two-arm crossover trial conducted in the US and Canada 
      with two 12-week periods comparing preference between preprandial human insulin 
      inhalation powder (HIIP; AIR inhaled insulin) and preprandial SC insulin (regular 
      human insulin or insulin lispro) in patients with type 1 diabetes. Patients 
      received HIIP plus insulin glargine during period 1 and SC insulin plus insulin 
      glargine during period 2, or the reverse sequence. MAIN OUTCOME MEASURES: SF-36 
      Vitality Subscale, Diabetes Symptom Checklist-Revised subscales, Diabetes 
      Treatment Satisfaction Questionnaire, Insulin Delivery System Questionnaire, 
      HIIP-specific questionnaire, preference question. RESULTS: Of 137 patients 
      entered, 119 completed the study (54% female, mean age 40.9 +/- 12.4 years, mean 
      HbA(1C) 8.1 +/- 1.0%). Patients had significantly greater treatment satisfaction 
      and more positive evaluation of their insulin delivery system (easier to control 
      blood sugar, less lifestyle impact) with HIIP than with SC insulin (all p < 
      0.01). Patients preferring HIIP (80%) were significantly more confident about (p 
      = 0.005) and comfortable with (p = 0.003) using the system than those preferring 
      SC insulin. Results may not be generalizable to all patients with type 1 
      diabetes. CONCLUSIONS: Some patients desire alternatives to insulin injection. In 
      this study 80% preferred HIIP to injected insulin. Other patients feel more 
      comfortable with familiar insulin delivery. Healthcare providers should help 
      patients find insulin delivery that corresponds to individual preferences.
FAU - Hayes, Risa P
AU  - Hayes RP
AD  - Global Health Outcomes, Eli Lilly and Company, Lilly Corporate Center, 
      Indianapolis, IN 46285, USA. hayes_clarice@lilly.com
FAU - Muchmore, Douglas
AU  - Muchmore D
FAU - Schmitke, Jennifer
AU  - Schmitke J
LA  - eng
SI  - ClinicalTrials.gov/NCT00063128
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin Lispro)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Powders)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 1/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Insulin/administration & dosage/*analogs & derivatives/*therapeutic use
MH  - Insulin Glargine
MH  - Insulin Lispro
MH  - Insulin, Long-Acting
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction/*statistics & numerical data
MH  - Powders
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2007/02/10 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/02/10 09:00
PHST- 2007/02/10 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/10 09:00 [entrez]
AID - 10.1185/030079906X167381 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Feb;23(2):435-42. doi: 10.1185/030079906X167381.